贝伐珠单抗联合S-1/伊立替康对比mFOLFOX6/CapeOX一线治疗转移性结直肠癌:TRICOLORE研究RAS状态与肿瘤部位探索性分析
TRICOLORE试验显示,S-1联合伊立替康加贝伐珠单抗一线治疗转移性结直肠癌的无进展生存期非劣于mFOLFOX6/CapeOX加贝伐珠单抗,总生存期数据在初步分析时不成熟。本文报告最终总生存期分析及RAS状态和原发肿瘤部位的探索性结果,中位随访48.7个月,两组中位总生存期分别为32.6和34.3个月(HR 0.89,95%CI 0.72-1.10,P=0.293),中位无进展生存期分别为10.8和14.0个月(HR 0.86,95%CI 0.71-1.04,非劣效性P<0.0001)。
要点
- S-1/伊立替康+贝伐珠单抗一线治疗mCRC的总生存期与mFOLFOX6/CapeOX+贝伐珠单抗相当。
- 实验组无进展生存期非劣于对照组,中位14.0个月 vs 10.8个月(HR 0.86)。
- 左半RAS野生型患者中实验组无进展生存期更优(16.9 vs 11.4个月,HR 0.68,P=0.028)。
核心结论
- S-1联合伊立替康加贝伐珠单抗一线治疗mCRC的总生存期与mFOLFOX6/CapeOX加贝伐珠单抗相当,无进展生存期非劣。
- 推荐S-1联合伊立替康加贝伐珠单抗作为mCRC标准一线方案,不受肿瘤部位或RAS状态影响。
研究设计与样本
- 随机、开放标签、III期非劣效性试验(TRICOLORE),纳入53家机构共487例既往未治疗的mCRC患者,1:1随机分配。
- 对照组接受mFOLFOX6/CapeOX加贝伐珠单抗,实验组接受S-1联合伊立替康加贝伐珠单抗(3周或4周方案)。
- 最终总生存期数据基于截至2017年9月30日收集的随访数据分析。
主要发现
- 中位随访48.7个月,对照组和实验组中位总生存期分别为32.6和34.3个月(HR 0.89,95%CI 0.72-1.10,P=0.293)。
- 对照组和实验组中位无进展生存期分别为10.8和14.0个月(HR 0.86,95%CI 0.71-1.04,非劣效性P<0.0001)。
- 左半RAS野生型肿瘤患者中,对照组和实验组中位无进展生存期分别为11.4和16.9个月(HR 0.68,95%CI 0.48-0.96,P=0.028)。
临床怎么用
- S-1联合伊立替康加贝伐珠单抗可作为mCRC一线标准方案,不受肿瘤部位或RAS状态限制。
- 对于左半RAS野生型mCRC患者,该方案的无进展生存期获益更明显(HR 0.68)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. METHODS: In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. RESULTS: With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72-1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71-1.04, P < 0.0001 for non-inferiority). In patients with left-sided RAS wild-type tumours, median PFS durations were 11.4 and 16.9 months in the control and experimental groups, respectively (HR: 0.68, 95% CI: 0.48-0.96, P = 0.028). CONCLUSION: S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC. We recommend the use of S-1 and irinotecan plus bevacizumab as a standard first-line regimen independent of tumour sidedness or RAS status in mCRC. TRIAL REGISTRATION: UMIN-CTR: 000007834.
引用
- Denda T, Takashima A, Gamoh M, et al. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Eur J Cancer. 2021. PMID: 34304054. doi:10.1016/j.ejca.2021.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。